Nektar Therapeutics’ legal dispute with Eli Lilly took another turn as investors digested a $90 million jury award in Nektar’s favor over Lilly’s termination of a co-development collaboration. The case centered on Lilly’s alleged breach of an implied covenant of good faith and fair dealing tied to rezpegaldesleukin (rezpeg). Despite the jury verdict, shares ended flat, reflecting market focus on expectations versus the award size Nektar had sought. Analysts noted that the modeling impact was limited because Nektar did not rely on the case proceeds to continue advancing pipeline assets. The decision underscores how partnership contracts and milestone alignment can materially affect development strategy and financing assumptions in mid-stage biotech pipelines.